Clifford Samuel has 25+ years of commercial leadership experience in the biopharmaceutical industry, with more than two decades at Gilead Sciences in leadership roles across sales, managed markets, global health policy and global commercial operations. For the last five years, he served as Senior Vice President, Global Patient Solutions, with responsibility for commercial operations and access in more than 140 countries. Propelled by his mission to ensure large-scale access to Gilead’s life-saving medicines, Clifford identified market potential and enabled the delivery of medicines to millions in emerging markets, while increasing revenue by billions. He spearheaded Gilead’s entry into generic licensing agreements with companies in China, India and South Africa that created a competitive market for generic HIV and hepatitis B & C medicines. Executed, at dramatically reduced prices, his efforts deliver medicines to more than 18 million people in these resource-limited countries.
In devising and implementing innovative manufacturing, distribution, and go-to-market strategies, Clifford leverages his operational excellence skills, as well as his knowledge of the regulatory landscape and distribution network across the globe. He built novel global strategic partnerships, including collaborations with governments, non-governmental organizations, global health and generic drug manufacturers.
Clifford is internationally recognized for major advancements in engineering and developing and implementing innovative approaches to engineering STEM education. A graduate of the New Jersey Institute of Technology (NJIT) with a BS in Mechanical Engineering, he received an honorary PhD from his alma mater and sits as an NJIT Honor Program Board Member. He is also the recipient of an Edward F. Weston Medal for Professional Achievement (NJIT) and a member of the American Institute for Medical and Biological Engineering (AIMBE). Clifford is also a member of the U.S. National Academy of Engineering in 2019.